New drug combo aims to unleash immune system against advanced melanoma
NCT ID NCT03161431
First seen Dec 29, 2025 · Last updated May 23, 2026 · Updated 26 times
Summary
This early-stage study tests a new drug, SX-682, combined with the immunotherapy pembrolizumab in people with advanced melanoma. The goal is to see if SX-682 can block cancer's ability to hide from the immune system, making the immunotherapy more effective. About 77 participants will receive SX-682 alone for 21 days, then both drugs together for up to 2 years. The study focuses on safety and finding the best dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA STAGE III are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
MD Anderson
Houston, Texas, 77030, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
University of Miami
Miami, Florida, 33136, United States
-
Wilmot Cancer Institute - University of Rochester
Rochester, New York, 14642, United States
Conditions
Explore the condition pages connected to this study.